SIRS-Lab wins CE Mark for new sepsis test

With Vyoo, clinicians can rapidly and reliably identify causative pathogens as well as important antibiotic resistance markers. Vyoo allows for a customized anti-infective therapy in each patient within the critical hours of treatment, the company said.

The CE Mark will accelerate the implementation of Vyoo into clinical routine throughout Europe.

Stefan Russwurm, CEO of SIRS-Lab, said: “In important European clinical centers, for example in Paris or Basel, patients already benefit from the therapeutic advantages provided by Vyoo. With the CE status, the full potential of this ground-breaking approach to sepsis diagnostics will be realized.”